User: Guest  Login
Title:

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

Document type:
Journal Article; Article
Author(s):
Laika, B; Leucht, S; Heres, S; Steimer, W
Abstract:
The cytochrome P450 2D6 (CYP2D6) isoenzyme metabolizes about 25% of clinically used drugs. The impact of CYP2D6 metabolizer status on therapeutic outcome was assessed in 365 psychiatric in-patients treated with neuroleptics or antidepressants. Length of hospitalization and response onset were prolonged for patients receiving CYP2D6 drugs. Intermediate metabolizers (IMs) receiving CYP2D6 doses above the population median had more side effects after 4 weeks than extensive metabolizers with above-m...     »
Journal title abbreviation:
Pharmacogenomics J
Year:
2009
Journal volume:
9
Journal issue:
6
Pages contribution:
395-403
Language:
eng
Fulltext / DOI:
doi:10.1038/tpj.2009.23
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/19451914
Print-ISSN:
1470-269X
TUM Institution:
Institut für Klinische Chemie und Pathobiochemie; Klinik und Poliklinik für Psychiatrie und Psychotherapie
 BibTeX